The uncertain future of antibody claims

A long string of decisions from the US Court of Appeals for the Federal Circuit has undermined support for purely functional antibody epitope claims through the written description and enablement requirements of 35 USC §112.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Amgen antibody patents ‘too broad’, says Fed Circuit

16 February 2021 The US Court of Appeals for the Federal Circuit has invalidated two Amgen antibody patents, finding that their functional claims were too broad.

Big Pharma

Sanofi and C4X in $493m licensing deal

13 April 2021 UK company C4X Discovery has agreed an exclusive licensing deal with Sanofi worth a potential €414 million, which will see the French pharmaceutical company develop anti-inflammatory therapies.

Americas

Haynes Boone hires top biotech patent lawyer

19 July 2022 New partner boosts firm’s biotech practice | Move forms part of life sciences expansion | Role based at Washington, DC office.

More on this story

Americas

Amgen antibody patents ‘too broad’, says Fed Circuit

16 February 2021 The US Court of Appeals for the Federal Circuit has invalidated two Amgen antibody patents, finding that their functional claims were too broad.

Big Pharma

Sanofi and C4X in $493m licensing deal

Americas

Haynes Boone hires top biotech patent lawyer

19 July 2022 New partner boosts firm’s biotech practice | Move forms part of life sciences expansion | Role based at Washington, DC office.

More on this story

Americas

Amgen antibody patents ‘too broad’, says Fed Circuit

16 February 2021 The US Court of Appeals for the Federal Circuit has invalidated two Amgen antibody patents, finding that their functional claims were too broad.

Big Pharma

Sanofi and C4X in $493m licensing deal

Americas

Haynes Boone hires top biotech patent lawyer

19 July 2022 New partner boosts firm’s biotech practice | Move forms part of life sciences expansion | Role based at Washington, DC office.